TrianglePUBLICATIONS · 30124753
Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- Ann Oncol
- Publication date
- 2018 Sep 1
- First author
- Ettl J
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Ettl J
- type
- Author
- name
- Quek RGW
- type
- Author
- name
- Lee KH
- type
- Author
- name
- Rugo HS
- type
- Author
- name
- Hurvitz S
- type
- Author
- name
- Gonçalves A
- type
- Author
- name
- Fehrenbacher L
- type
- Author
- name
- Yerushalmi R
- type
- Author
- name
- Mina LA
- type
- Author
- name
- Martin M
- type
- Author
- name
- Roché H
- type
- Author
- name
- Im YH
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Ettl J
- type
- Author
- name
- Quek RGW
- type
- Author
- name
- Lee KH
- type
- Author
- name
- Rugo HS
- type
- Author
- name
- Hurvitz S
- type
- Author
- name
- Gonçalves A
- type
- Author
- name
- Fehrenbacher L
- type
- Author
- name
- Yerushalmi R
- type
- Author
- name
- Mina LA
- type
- Author
- name
- Martin M
- type
- Author
- name
- Roché H
- type
- Author
- name
- Im YH
- type
- Author
- bibliography ids
- nci-bib-ee7c04ecddce279288d1a625
- book metadata
- content sha256
- 7d88cd9be3adb89d3dddd56c3ae996874c789decff157f88d26a0b4204fa0a4f
- document type
- citation
- dois
- 10.1093/annonc/mdy257
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:30124753
- immutable id
- pubmed:30124753@7d88cd9be3adb89d3dddd56c3ae996874c789decff157f88d26a0b4204fa0a4f
- journal
- abbreviation
- Ann Oncol
- issn electronic
- 1569-8041
- issn print
- 0923-7534
- issue
- 9
- name
- Annals of oncology : official journal of the European Society for Medical Oncology
- nlm unique id
- 9007735
- pages
- 1939-1947
- volume
- 29
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 30124753
- provenance
- batch id
- 438b2803888025c6cf56
- provider
- NCBI PubMed ESummary
- record sha256
- adef0f18241715e36362c8ff4296bfc3b01330b0a7189b75d49461119f11c50e
- response sha256
- 0adf5ff07d3aa03a45feef5e4b7998e2ddea370eb9d1c6aa9134c5fd329767e6
- retrieved at
- 2026-09-09T23:47:36.359220+00:00
- publication date
- display
- 2018 Sep 1
- precision
- day
- year
- 2018
- publication types
- Clinical Trial, Phase III
- Comparative Study
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial.
Preserved source evidence · Not medical advice